Adma Biologics is a biotechnology company that specializes in the development and manufacturing of immune globulin therapies and other biologics for patients suffering from immune deficiencies and specific infectious diseases. The company focuses on harnessing human plasma to create products that can improve immune response and provide critical support for individuals with compromised immune systems. Through its innovative research and commitment to quality, Adma aims to deliver safe and effective therapies that enhance patient outcomes and overall health. Read More
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ: ADMA) securities between August 9, 2024 and March 25, 2026, inclusive (the “Class Period”). ADMA investors have until August 10, 2026 to file a lead plaintiff motion.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ADMA Biologics To Contact Him Directly To Discuss Their Options
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ADMA Biologics, Inc. (“ADMA” or “the Company”) (NASDAQ: ADMA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ:ADMA) securities during the period of August 9, 2024 through March 25, 2026, inclusive (“the Class Period”).
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ADMA Biologics, Inc. (“ADMA” or the “Company”) (NasdaqGM: ADMA) of a class action securities lawsuit.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In ADMA To Contact Him Directly To Discuss Their Options
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against ADMA Biologics, Inc. (“ADMA Biologics” or the “Company”) (NASDAQ: ADMA) and reminds investors of the August 10, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ: ADMA) securities between August 9, 2024 and March 25, 2026, inclusive (the “Class Period”). ADMA investors have until August 10, 2026 to file a lead plaintiff motion.
Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against ADMA Biologics, Inc. (NASDAQ:ADMA) and certain of the Company’s senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws.
Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ADMA Biologics, Inc. (NASDAQ: ADMA) securities between August 9, 2024 and March 25, 2026. ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for ADMA Biologics investors under the federal securities laws.
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ: ADMA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ: ADMA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating ADMA Biologics (NASDAQ: ADMA) (“ADMA Biologics” or the “Company”) for potential violations of the federal securities laws.
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ: ADMA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating ADMA Biologics (NASDAQ: ADMA) (“ADMA Biologics” or the “Company”) for potential violations of the federal securities laws.
